An interventional study of Mid-Ohio Food Farmacy (MOF+) produce delivery and Nutrition education with Dining with Diabetes (DWD) in Type 2 Diabetes, Type 1 Diabetes and Pregnancy, High Risk, sponsored by Ohio State University. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-14.
Sponsored by Ohio State University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Diabetes Mellitus, Type 2 by Ohio State University — 8 open to participants now, 9 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Ohio State University.
Among the 18 studies in Diabetes Mellitus, Type 2 by Ohio State University, this one is the 7th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2026, is one of 13 with no phase, and was the 18th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →8 of the 18 studies in Diabetes Mellitus, Type 2 by Ohio State University are open now, in 1 country. Recruiting first, the newest first:
Ohio State University · Sites in United States
Ages 18+ · Women only
Ohio State University · Sites in United States
Ages 18+ · Women only
Ohio State University · Sites in United States
Ages 18+ · Women only
Ohio State University · Sites in United States
Ages 18+ · Women only
Ohio State University · Sites in United States
Ages 18–80
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 4 1
First in 2003; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 174 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 141 across the 16 interventional studies, 72 across the 2 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ohio State University is the lead sponsor of 664 studies on the registry; 149 are open to participants now.
Of its 67 completed or terminated interventional studies of FDA-regulated products, 49 (73%) have results posted.
5 of the studies in Diabetes Mellitus, Type 2 by Ohio State University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05909046Ohio State UniversityA Randomized Controlled Trial of Diabetes Screening Immediately Postpartum (DIP) and Follow Up PP CARE | 2026-12 |
| NCT05905575Ohio State UniversityA Family Dyad-focused Diabetes Self-Management Intervention for African American Adults | 2027-01-31 |
| NCT05472441Ohio State UniversityLinking Education, Produce Provision, and Community Referrals to Improve Diabetes Care (LINK) | 2027-03-31 |
| NCT07293715Ohio State UniversityPermissive Versus Strict Intrapartum Glucose Management in Type 1 and Type 2 Diabetes (PRISM) | 2027-06 |
| NCT06078683Ohio State UniversityEffects of Ketone Ester Consumption on Exercise Tolerance and Cardiac Function | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 18 studies in Diabetes Mellitus, Type 2 by Ohio State University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Nutrition insecurity (inclusive of food insecurity + poor diet quality) is a fundamental social need that must be addressed to improve treatment and health outcomes for high-risk pregnant women with pregestational type 1 and 2 diabetes, poor glucose control, and food insecurity for whom a healthy diet is critical. The NOURISH trial will provide evidence of a scalable, integrated, and theory-based healthcare-community partnership that includes weekly nutritious produce home delivery, monthly clinic-integrated diabetes, nutrition, and culinary group education, and continuous social needs assessment and support to improve glucose control and pregnancy outcomes. Given the increasing burden and devasting consequences of nutrition insecurity among high-risk pregnant women with diabetes and unmet social needs, NOURISH-an innovative and sustainable healthcare-community partnership-will have significant public health benefit.
Nutrition insecurity (inclusive of food insecurity + poor diet quality) is a fundamental non-medical, health-related social need that impacts >20% of pregnant women and up to 50% of individuals with pregestational diabetes in the United States. Nutrition insecurity has devastating health consequences for the >100,000 pregnant women with pregestational diabetes (type 1 or 2) and their exposed infants every year for whom a healthy diet is critical. Pregnant women with pregestational diabetes and nutrition insecurity are more likely to experience poor glycemic control, and as a result, adverse pregnancy outcomes. The risk of these adverse health outcomes increases when glycemic control is not achieved and social needs go unaddressed. Enhancing healthy food access and providing nutrition education-i.e., building "nutrition security"-is critical to improving outcomes for pregnant women with diabetes and poor glycemic control.
Our transdisciplinary team designed NOURISH: a theory- and evidence-based and collaborative healthcare-community partnership to enhance healthy food access, provide nutrition education and support, and address unmet social needs to improve glycemic control and pregnancy outcomes for high-risk pregnant women with pregestational diabetes, poor glycemic control, and food insecurity. The investigators propose the tripartite sustainable NOURISH intervention: 1) weekly nutritious produce home delivery by the Mid-Ohio Farmacy (MOF+), 2) monthly clinic-integrated diabetes, nutrition, and culinary group education by the OSU Cooperative Extension's Dining with Diabetes Program (DWD), and 3) continuous community health worker-led social needs assessment and support by the Health Impact Ohio Central Ohio Pathways Hub (Hub). Our central hypothesis is the combined NOURISH intervention (MOF + DWD + Hub) versus standard care will achieve glycemic control (hemoglobin A1c \<6.5% by delivery), prevent adverse pregnancy outcomes (gestational weight gain and neonatal morbidity), and improve diet quality and nutrition security. The investigators will randomize 174 eligible pregnant women (87 NOURISH, 87 standard care) with pregestational diabetes, poor glycemic control, and food insecurity.
The investigators will accomplish three specific aims: 1: use a pragmatic randomized controlled trial to test the effect of NOURISH-enhanced nutrition provision (MOF+), nutrition and diabetes education (DWD), and social needs referrals (Hub)-on improving glycemic control by delivery and secondarily, pregnancy outcomes (maternal gestational weight gain, neonatal morbidity), nutrition quality, and nutrition security.; 2: use cost- effectiveness analysis to assess the NOURISH intervention's value relative to standard care; and 3: use process evaluation to characterize intervention and contextual factors influencing uptake, effectiveness, and sustainability of the NOURISH intervention. NOURISH is a scalable and mutually beneficial healthcare-community partnership to improve nutrition security, glycemic control, and outcomes for pregnant women living with diabetes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
criteria:
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the NOURISH intervention group will be enrolled in the Mid-Ohio Farmacy program to receive home delivery of healthy food and produce from the Mid-Ohio Food Collective up to once a week and access to nutrition education and community resources. They may be invited to participate in an optional interview about their experience. Participants will be asked to complete surveys about their diet and nutrition and experiences living with diabetes and pregnancy.
Dietary Supplement: Mid-Ohio Food Farmacy (MOF+) produce delivery · Behavioral: Nutrition education with Dining with Diabetes (DWD) · Behavioral: Health Impact Ohio Central Ohio Pathways Hub to address unmet social needs
Participants in the standard of care group will receive access to community resources to support their diet during pregnancy, be asked to complete surveys about their diet and nutrition and experiences living with diabetes and pregnancy. They may be invited to participate in an optional interview about their experience. Participants will be given access to community resources about nutrition for which they may qualify. At the completion of the study, participants will be encouraged to enroll and utilize the Mid-Ohio Farmacy program.
The Mid-Ohio Food Collective (MOFC) is a regional foodbank that delivers \>170,000 meals daily through 680 agency partnerships and is ranked as one of the 10 largest in the U.S. Both OSUWMC and MOFC are located in a large metropolitan region in Ohio. OSUWMC offers the Mid-Ohio Farmacy (MOF) referral in nine clinics, including an integrated diabetes and prenatal care clinic for pregnant individuals with pregestational diabetes, with OSUWMC funding secured to continue this program. The goal of the MOF is to establish a systematic screening and referral process aimed at addressing food insecurity that connects patients to fresh produce through a food pantry near their home. In NOURISH: The investigators will extend the existing MOF program to weekly home delivery of produce coordinated by the Food Collective. Weekly MOF+ deliveries will include 15 to 20 pounds per week of low to medium glycemic index fruits and vegetables from available inventory, as recommended by the USDA.
The investigators will deploy OSU Extension's community-based education program, DWD, with live programming focused on cooking instruction from the OSU-based Cooking Matters (CM) program, which actively engages participants to develop skills for healthy eating. Working with our diabetes education team from DWD, the investigators have tailored this program to target the specific needs of pregnant individuals with pregestational diabetes. This includes in-person 1 hour group sessions every 4 weeks (monthly) at the time of clinic visits with alternating education sessions provided by DWD with interactive hands-on cooking sessions provided by CM. The nutrition portion focuses on healthy eating and blood glucose management, and the cooking portion provides education on food safety, knife techniques, nutrition facts and ingredients label reading, meal planning, budgeting, and shopping. Content will be adapted from state-approved curricula for pregnancy and the American Diabetes Association.
Health Impact Ohio Central Ohio Pathways Hub. The Pathways Community Hub ('Hub') model consists of three features: (1) the Hub is a regional coordination entity that employs CHWs to assess the medical and social needs of vulnerable patients and connect them to community resources; (2) the CHWs initiate a "care pathway," a defined action plan that describes how patient needs will be addressed, which is then recorded and tracked in an electronic database; and (3) completion of each care pathway is linked to payment from insurance companies (Medicaid-managed care plans and other community partners) based on specific performance benchmarks. Specifically, a financial contract is attached to each standardized care pathway: When a care pathway is completed, a CHW must confirm that a measurable outcome (e.g., patient is assigned to a medical home) is obtained in order to receive an insurance payment.
The primary clinical outcome is the proportion of participants with an A1c <6.5% before delivery.
The primary outcome of A1c \<6.5% versus A1c ≥6.5% will be assessed according to the A1c most proximate to the time of delivery, and is consistent with current clinical guidelines to prevent adverse pregnancy outcomes for the mother and infant. The frequencies of adverse pregnancy outcomes are significantly decreased with an A1c \<6%. A1c typically will be assessed once per trimester, consistent with guidelines for the management of pregestational diabetes, and at delivery. The value closest to delivery will be used for participants with \>1 A1c value in the third trimester. The investigators will evaluate A1c using a standard assay and as an absolute percentage of total hemoglobin.
Time frame: Approximately once per trimester every 12-14 weeks betwee trial enrollment through 6-12 weeks postpartum.
Gestational weight gain (GWG) z-score
The secondary outcome of maternal GWG will be defined as the GWG z-score within versus above or below pregnancy recommendations per the Institute of Medicine guidelines. The Institute of Medicine guidelines for GWG include recommendations specific to pre-pregnancy body mass index (BMI) to optimize maternal and infant outcomes. The investigators will assess GWG with z-scores (PMID: 34839478). The investigators will convert absolute weight gain to z-scores using established charts specific to the 4 pre-pregnancy BMI groups and gestational age at delivery. This GWG z-score is not confounded by duration of pregnancy.
Time frame: Time from randomization in the first or second trimester of pregnancy through date of delivery, assessed up to 9 months
Composite neonatal outcome
The secondary composite neonatal outcome includes one (or more) of the following: large-for-gestational-age at birth, hypoglycemia, hyperbilirubinemia, preterm birth \<37 weeks, and neonatal intensive care unit admission. The individual components will be defined as: 1) Large-for-gestational age: birthweight ≥90th percentile per infant-sex standardized 2017 U.S. reference for singleton birthweight %tile; 2) Hypoglycemia: Capillary glucose \<35 mg/dL requiring glucose supplementation \<24 hours of birth; 3) Hyperbilirubinemia: Phototherapy without another cause of jaundice; 4) Preterm birth \<37 weeks, either spontaneous or medically-indicated; and 5) Neonatal intensive care unit admission for any indication.
Time frame: Time from delivery or birth of infant to discharge from the hospital, assessed up to 100 weeks
Nutrition security
The newly developed Gretchen Swanson Center for Nutrition Household Nutrition Security measure consists of 4 questions and is measured on a continuous measure. This measure aims to determine a household's ability to acquire nutritious foods that meet their health needs without resource challenges or worry. The measure includes 4 questions, which were scored from 0 to 4, where 4 corresponds to "Always" and 0 corresponds to "Never." Per the scoring protocol, the investigators will assess this outcome as a continuous measure from 0 to 4 and as a binary variable classifying individuals as "nutrition secure" (average score \>2) or "nutrition insecure" (average score ≤2).
Time frame: pproximately once per trimester every 12-14 weeks betwee trial enrollment through 6-12 weeks postpartum.
Plan to share: No
Started Jul 2026 (actual). Primary completion is estimated for Dec 2029, 41 months after the start.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 41 months is above that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.